Jyonouchi S, Gwafila B, Gwalani LA, Ahmad M, Moertel C, Holbert C, Kim JY, Kobrinsky N, Roy-Ghanta S, Orange JS. Phase I trial of low-dose interleukin 2 therapy in patients with Wiskott-Aldrich syndrome.
Clin Immunol 2017;
179:47-53. [PMID:
28232030 DOI:
10.1016/j.clim.2017.02.001]
[Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2016] [Revised: 12/21/2016] [Accepted: 02/10/2017] [Indexed: 12/19/2022]
Abstract
BACKGROUND
Low dose IL-2 can restore the function of T and NK cells from Wiskott-Aldrich (WAS) patients. However, the safety of in vivo IL-2 in WAS is unknown.
OBJECTIVES
A phase-I study to assess safety of low dose IL-2 in WAS.
METHODS
Patients received 5 daily subcutaneous IL-2 injections, every 2months, for three courses. A "3+3" dose escalation method was used.
RESULTS
6 patients received the 0.5millionunits/m2/day dose without serious adverse events. However, 2 of 3 patients receiving the 1millionunits/m2/day dose developed thrombocytopenia requiring platelet transfusions. A statistically significant platelet increase occurred in patients receiving the 0.5millionunits/m2/day dose. A trend toward higher T, B and NK cell numbers and higher T regulatory cell percentages was observed.
CONCLUSION
We have identified a safe IL-2 dose for WAS patients. Additional trials are indicated to study the efficacy of this immunostimulant as a therapy for WAS.
Collapse